Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Operations (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Cash from Operations for 11 consecutive years, with 33776000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 22.62% year-over-year to 33776000.0, compared with a TTM value of 187493000.0 through Dec 2025, down 24.15%, and an annual FY2025 reading of 187493000.0, down 24.15% over the prior year.
  • Cash from Operations was 33776000.0 for Q4 2025 at Wave Life Sciences, up from 44666000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 85522000.0 in Q1 2023 and bottomed at 63039000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 28736200.0, with a median of 33608000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations plummeted 375.47% in 2022, then skyrocketed 314.49% in 2023.
  • Year by year, Cash from Operations stood at 7033000.0 in 2021, then plummeted by 375.47% to 33440000.0 in 2022, then grew by 0.6% to 33239000.0 in 2023, then tumbled by 31.32% to 43648000.0 in 2024, then grew by 22.62% to 33776000.0 in 2025.
  • Business Quant data shows Cash from Operations for WVE at 33776000.0 in Q4 2025, 44666000.0 in Q3 2025, and 46012000.0 in Q2 2025.